About Motus GI
Motus GI Holdings, Inc. is a medical technology company dedicated to improving endoscopy outcomes and experiences.
CEO: Mark Pomeranz
CFO: Andrew Taylor
24 articles with Motus GI
Motus GI Announces Publication of Pure-Vu® System Clinical Study Data in Peer-Reviewed Endoscopy Journal
Published data show significant increase in the number of subjects with an adequate cleansing level to 100% from 19.1% at baseline after use of the Pure-Vu® System
Presentation with live audio webcast Tuesday, January 8, 2019 at 4:00 PM PST
Motus GI Holdings, Inc., announced the pricing of its follow-on public offering of 5,000,000 shares of its common stock at a price of $2.70 per share, for total gross proceeds of $13.5 million.
Motus GI Holdings, Inc., announced that it filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (SEC) relating to a proposed follow-on public offering of 5,000,000 shares of its common stock.
Ongoing market development programs continue to build foundation for full commercial launch of the Pure-Vu® System in 2019
Pure-Vu® Slim Sleeve provides broader procedural access to cover a full range of colonoscopes
Motus GI Presents Positive Clinical Data from U.S. Prospective Study of the Pure-Vu® System at the 2018 American College of Gastroenterology (ACG) Annual Meeting
Data demonstrates safety and effectiveness of the Pure-Vu® System in patients who had minimal preparation regimens and who were allowed to consume solid food the day before the procedure
Presentation with live audio webcast on Tuesday, October 2nd at 3:00 p.m. EDT
Motus GI Appoints Medical Device Commercial Leader Timothy P. Moran as Chief Executive Officer; Mark Pomeranz Continues in Key Executive Leadership Role as President and Chief Operating Officer
Combination of Moran’s proven commercial and leadership skills with Pomeranz’ extensive product scale-up and operational expertise positions company for Pure-Vu® launch and sustainable growth
Pure-Vu® Slim Sleeve provides broader procedural access to cover a full range of colonoscopes.
Building clinical and health economic evidence demonstrating potential value of the Pure-Vu® System in high need patient populations with focus on inpatient colonoscopy market.
Hutchison brings extensive background in innovative GI product sales and will lead development of commercial organization in preparation for 2019 launch
Expansion of global IP portfolio continues to lay foundation for future growth opportunities in key markets outside the United States
Six biotechs will end the month of June as new additions to the Russell Indexes. Approximately $9 trillion in assets are benchmarked against Russell U.S. Indexes, which are reconstituted annually.
Motus GI Presents Cost Analysis Data Demonstrating Pure-Vu® System Has the Potential to Reduce Costs and Incidence of Colorectal Cancer at Digestive Disease Week® 2018
Cost Analysis Data indicates Pure-Vu® System has the potential to reduce inadequate colon prep rate for colonoscopy, leading to lower costs and lower projected incidence of CRC in average and high-risk patients
Published studies show insufficient bowel prep can occur in over 55% of inpatient cases and lead to average of 2 day hospital stay extension and as much as $8,000 in additional costs
- Company successfully continues to expand global IP portfolio to support strategic pathway for Pure-Vu® System to become standard of care
Q1 2018 marked by significant corporate and clinical advancements, including successfully completing $17.5M IPO and listing on NASDAQ Capital Marke
Successfully completed $17.5M IPO and listed on NASDAQ Capital Market.
Motus GI Expands Intellectual Property Portfolio with New U.S. Patent Issuance for the Pure-Vu® System
Expansion of IP portfolio further supports Company’s strategic pathway for flagship product to become standard of care.